tradmap

OLMA Financials Olema Pharmaceuticals, Inc.

7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Revenue & net income
-$162M -$81M $0 2019 2020 2021 2022 2023 2024 2025
RevenueNet income
Margins (gross / operating / net)
0% 50% 100% 2019 2020 2021 2022 2023 2024 2025
GrossOperatingNet
Free cash flow (CFO − capex)
-$105M -$52M $0 2019 2020 2021 2022 2023 2024 2025
Free cash flow
Cash vs total debt
$0 $169M $339M 2019 2020 2021 2022 2023 2024 2025
CashTotal debt
Cash flow: operating / investing / financing
-$275M $41M $358M $0 2019 2020 2021 2022 2023 2024 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 -$162M $48M
2024 -$129M -$105M $139M
2023 -$97M $69M
2022 -$105M -$82M $24M
2021 -$71M -$52M $14M
2020 -$22M -$20M $339M
2019 -$4M

Frequently asked questions

Is OLMA growing its revenue and profit?

See the revenue and net-income charts above for Olema Pharmaceuticals, Inc.'s multi-year trend.

How much debt does OLMA have?

As of FY2025, Olema Pharmaceuticals, Inc. reported — of total debt against $48M of cash.

What is OLMA's profit margin?

In FY2025, gross margin was —, operating margin —, and net margin —.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.